{"id":"https://openalex.org/W4404172202","doi":"https://doi.org/10.1016/j.ejmech.2024.117040","title":"Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis","display_name":"Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis","publication_year":2024,"publication_date":"2024-11-08","ids":{"openalex":"https://openalex.org/W4404172202","doi":"https://doi.org/10.1016/j.ejmech.2024.117040","pmid":"https://pubmed.ncbi.nlm.nih.gov/39561495"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejmech.2024.117040","doi":"https://doi.org/10.1016/j.ejmech.2024.117040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejmech.2024.117040","pdf_url":null,"source":{"id":"https://openalex.org/S4210169613","display_name":"European Journal of Medicinal Chemistry","issn_l":"0223-5234","issn":["0223-5234","1768-3254"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejmech.2024.117040","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087804499","display_name":"Henry L. Danahay","orcid":"https://orcid.org/0009-0004-7180-752X","observed_orcids":["https://orcid.org/0009-0004-7180-752X"]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]},{"id":"https://openalex.org/I4405267302","display_name":"Enterprise Therapeutics Ltd. (United Kingdom)","ror":"https://ror.org/023en2f83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405267302"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Henry Danahay","raw_affiliation_strings":["Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom","institution_ids":["https://openalex.org/I162608824","https://openalex.org/I4405267302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035990360","display_name":"Martin Gosling","orcid":"https://orcid.org/0000-0003-1801-1333","observed_orcids":["https://orcid.org/0000-0003-1801-1333"]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]},{"id":"https://openalex.org/I4405267302","display_name":"Enterprise Therapeutics Ltd. (United Kingdom)","ror":"https://ror.org/023en2f83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405267302"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin Gosling","raw_affiliation_strings":["Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom","institution_ids":["https://openalex.org/I162608824","https://openalex.org/I4405267302"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Roy Fox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Roy Fox","raw_affiliation_strings":["Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom","institution_ids":["https://openalex.org/I162608824"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051616618","display_name":"Sarah J Lilley","orcid":"https://orcid.org/0000-0002-0236-2027","observed_orcids":["https://orcid.org/0000-0002-0236-2027"]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Lilley","raw_affiliation_strings":["Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom","institution_ids":["https://openalex.org/I162608824"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059540939","display_name":"Holly Charlton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Holly Charlton","raw_affiliation_strings":["Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom","institution_ids":["https://openalex.org/I162608824"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022644439","display_name":"Jonathan D. Hargrave","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jonathan D. Hargrave","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113244469","display_name":"Thomas B Schofield","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Thomas B. Schofield","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109983203","display_name":"Duncan A. Hay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Duncan A. Hay","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056746749","display_name":"Naomi E. Went","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Naomi Went","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Pearl McMahon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Pearl McMahon","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110502588","display_name":"Frederic J. Marlin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Frederic Marlin","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059284814","display_name":"John W. Scott","orcid":"https://orcid.org/0000-0002-1896-9798","observed_orcids":["https://orcid.org/0000-0002-1896-9798"]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Scott","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069441119","display_name":"Julia Vile","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Julia Vile","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055779689","display_name":"S. Hewison","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Steve Hewison","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114566348","display_name":"Sarah Ellam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Ellam","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Samantha Brown","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148098","display_name":"Evotec (United Kingdom)","ror":"https://ror.org/04qvy9k41","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210130816","https://openalex.org/I4210148098"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Samantha Brown","raw_affiliation_strings":["Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom","institution_ids":["https://openalex.org/I4210148098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103382319","display_name":"Juan R. Sabater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095266","display_name":"Mount Sinai Medical Center","ror":"https://ror.org/00wgjpw02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210095266"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juan Sabater","raw_affiliation_strings":["Department of Research, Mount Sinai Medical centre, 4300 Alton Rd, Miami Beach FL 3340, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Research, Mount Sinai Medical centre, 4300 Alton Rd, Miami Beach FL 3340, USA","institution_ids":["https://openalex.org/I4210095266"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114566349","display_name":"Guy Kennet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I71052956","display_name":"University of Reading","ror":"https://ror.org/05v62cm79","country_code":"GB","type":"education","lineage":["https://openalex.org/I71052956"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Guy Kennet","raw_affiliation_strings":["Saretius, Whiteknights House (B10), University of Reading, Reading, RG6 6UR, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saretius, Whiteknights House (B10), University of Reading, Reading, RG6 6UR, United Kingdom","institution_ids":["https://openalex.org/I71052956"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021307288","display_name":"Sean Lightowler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I71052956","display_name":"University of Reading","ror":"https://ror.org/05v62cm79","country_code":"GB","type":"education","lineage":["https://openalex.org/I71052956"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sean Lightowler","raw_affiliation_strings":["Saretius, Whiteknights House (B10), University of Reading, Reading, RG6 6UR, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saretius, Whiteknights House (B10), University of Reading, Reading, RG6 6UR, United Kingdom","institution_ids":["https://openalex.org/I71052956"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051520885","display_name":"Stephen P. Collingwood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I162608824","display_name":"University of Sussex","ror":"https://ror.org/00ayhx656","country_code":"GB","type":"education","lineage":["https://openalex.org/I162608824"]},{"id":"https://openalex.org/I4405267302","display_name":"Enterprise Therapeutics Ltd. (United Kingdom)","ror":"https://ror.org/023en2f83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405267302"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Stephen P. Collingwood","raw_affiliation_strings":["Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom. Electronic address: steve@enterprisetherapeutics.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom. Electronic address: steve@enterprisetherapeutics.com","institution_ids":["https://openalex.org/I162608824","https://openalex.org/I4405267302"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5051520885"],"corresponding_institution_ids":["https://openalex.org/I162608824","https://openalex.org/I4405267302"],"apc_list":{"value":4850,"currency":"USD","value_usd":4850},"apc_paid":{"value":4850,"currency":"USD","value_usd":4850},"fwci":1.5513,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.80608649,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"282","issue":null,"first_page":"117040","last_page":"117040"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.7773000001907349,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.7773000001907349,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.19709999859333038,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12412","display_name":"Enzyme function and inhibition","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cystic-fibrosis","display_name":"cystic fibrosis","score":0.925000011920929},{"id":"https://openalex.org/keywords/pyrrolopyrazines","display_name":"pyrrolopyrazines","score":0.9129999876022339},{"id":"https://openalex.org/keywords/cftr-modulators","display_name":"CFTR modulators","score":0.7020000219345093},{"id":"https://openalex.org/keywords/airway-hydration","display_name":"airway hydration","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pulmonary-drug-delivery","display_name":"pulmonary drug delivery","score":0.8460000157356262},{"id":"https://openalex.org/keywords/lung-retention","display_name":"lung retention","score":0.625},{"id":"https://openalex.org/keywords/mucociliary-clearance","display_name":"mucociliary clearance","score":0.9409999847412109},{"id":"https://openalex.org/keywords/cftr","display_name":"CFTR","score":0.35499998927116394},{"id":"https://openalex.org/keywords/drug-design-and-synthesis","display_name":"drug design and synthesis","score":0.41600000858306885}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8077168464660645},{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.7649495601654053},{"id":"https://openalex.org/C81917197","wikidata":"https://www.wikidata.org/wiki/Q628760","display_name":"Selection (genetic algorithm)","level":2,"score":0.53480064868927},{"id":"https://openalex.org/C6507245","wikidata":"https://www.wikidata.org/wiki/Q424948","display_name":"Epithelial sodium channel","level":3,"score":0.4999659061431885},{"id":"https://openalex.org/C143724316","wikidata":"https://www.wikidata.org/wiki/Q312468","display_name":"Series (stratigraphy)","level":2,"score":0.44776424765586853},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43526893854141235},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.34571701288223267},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2378515899181366},{"id":"https://openalex.org/C537181965","wikidata":"https://www.wikidata.org/wiki/Q658","display_name":"Sodium","level":2,"score":0.0810244083404541},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000280","descriptor_name":"Administration, Inhalation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003550","descriptor_name":"Cystic Fibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019005","descriptor_name":"Cystic Fibrosis Transmembrane Conductance Regulator","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D019005","descriptor_name":"Cystic Fibrosis Transmembrane Conductance Regulator","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019005","descriptor_name":"Cystic Fibrosis Transmembrane Conductance Regulator","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053503","descriptor_name":"Epithelial Sodium Channels","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D053503","descriptor_name":"Epithelial Sodium Channels","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D062686","descriptor_name":"Epithelial Sodium Channel Blockers","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.ejmech.2024.117040","doi":"https://doi.org/10.1016/j.ejmech.2024.117040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejmech.2024.117040","pdf_url":null,"source":{"id":"https://openalex.org/S4210169613","display_name":"European Journal of Medicinal Chemistry","issn_l":"0223-5234","issn":["0223-5234","1768-3254"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:39561495","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39561495","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of medicinal chemistry","raw_type":"Journal Article"},{"id":"pmh:oai:figshare.com:article/28768952","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Optimisation_of_a_novel_series_of_ENaC_inhibitors_leading_to_the_selection_of_the_long-acting_inhaled_clinical_candidate_ETD001_a_potential_new_treatment_for_cystic_fibrosis/28768952","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1016/j.ejmech.2024.117040","doi":"https://doi.org/10.1016/j.ejmech.2024.117040","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejmech.2024.117040","pdf_url":null,"source":{"id":"https://openalex.org/S4210169613","display_name":"European Journal of Medicinal Chemistry","issn_l":"0223-5234","issn":["0223-5234","1768-3254"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Medicinal Chemistry","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1728651114","https://openalex.org/W1979040675","https://openalex.org/W2041286264","https://openalex.org/W2062564391","https://openalex.org/W2071954761","https://openalex.org/W2085746985","https://openalex.org/W2087893811","https://openalex.org/W2089214886","https://openalex.org/W2099204955","https://openalex.org/W2103722092","https://openalex.org/W2129631746","https://openalex.org/W2147868143","https://openalex.org/W2158888624","https://openalex.org/W2312795520","https://openalex.org/W2317516580","https://openalex.org/W2883215091","https://openalex.org/W2896241302","https://openalex.org/W2898244852","https://openalex.org/W2945205984","https://openalex.org/W2947794528","https://openalex.org/W3046225049","https://openalex.org/W3093770853","https://openalex.org/W3163966710","https://openalex.org/W3201137629","https://openalex.org/W4210526629","https://openalex.org/W4214743895","https://openalex.org/W4245135318","https://openalex.org/W4281251038","https://openalex.org/W4312959555","https://openalex.org/W4389941506","https://openalex.org/W6848776047"],"related_works":["https://openalex.org/W7213369197","https://openalex.org/W7163204904","https://openalex.org/W4417083776","https://openalex.org/W4399458556","https://openalex.org/W4281766313","https://openalex.org/W4389941506","https://openalex.org/W2005102655","https://openalex.org/W4214743895","https://openalex.org/W2947488566","https://openalex.org/W2734591047"],"abstract_inverted_index":{"Cystic":[0],"Fibrosis":[1],"(CF)":[2],"results":[3],"from":[4],"the":[5,10,24,33,87,91,98,107,119,132,149,152,186,193],"loss":[6],"of":[7,9,20,32,56,86,94,111,126,136,151,157,179,188,192,212],"function":[8],"cystic":[11],"fibrosis":[12],"transmembrane":[13],"conductance":[14],"regulator":[15],"(CFTR),":[16],"an":[17,48,69,77],"ion":[18],"channel":[19,61],"key":[21],"importance":[22],"in":[23,97,185,208,229,232],"airway":[25],"epithelia.":[26],"CFTR":[27,41,64],"helps":[28],"control":[29],"optimal":[30],"hydration":[31,85],"airways,":[34],"a":[35,142,203,209,225],"crucial":[36],"requirement":[37],"for":[38,52,115,145],"healthy":[39],"lungs.":[40],"modulators":[42],"have":[43,102],"recently":[44],"been":[45],"approved":[46],"as":[47,101],"effective":[49],"treatment":[50],"option":[51],"many":[53],"genetic":[54],"variants":[55],"CF.":[57],"The":[58,170],"epithelial":[59],"sodium":[60],"(ENaC),":[62],"unlike":[63],"which":[65],"is":[66,68,76,129],"secretory,":[67],"absorptive":[70],"pathway,":[71],"and":[72,79,109,202,205],"therefore":[73],"its":[74],"inhibition":[75,96,178],"alternative":[78],"potentially":[80],"complementary":[81],"approach":[82],"to":[83,90,118,165],"aid":[84],"airways.":[88],"Due":[89],"adverse":[92],"effect":[93,207],"ENaC":[95,113,127,180],"kidney":[99],"we,":[100],"several":[103],"others,":[104],"focused":[105,160],"on":[106,161],"design":[108],"synthesis":[110],"novel":[112],"inhibitors":[114,128,138],"direct":[116],"delivery":[117],"airways":[120,187],"via":[121],"inhalation.":[122],"A":[123],"new":[124],"series":[125],"described,":[130],"wherein":[131],"well-established":[133],"pyrazine":[134],"core":[135],"first-generation":[137],"was":[139],"replaced":[140],"with":[141],"pyrrolopyrazine.":[143],"Aiming":[144],"high":[146],"retention":[147,184],"at":[148],"surface":[150],"lung":[153],"following":[154,199,215],"inhalation,":[155],"optimisation":[156],"this":[158],"template":[159],"significantly":[162],"increasing":[163],"polarity":[164],"minimize":[166],"passive":[167],"cellular":[168],"permeability.":[169],"resulting":[171],"optimized":[172],"clinical":[173],"candidate":[174],"ETD001":[175,223],"demonstrates":[176],"potent":[177,204],"(59":[181],"nM)":[182],"prolonged":[183],"rats":[189],"(13":[190],"%":[191],"delivered":[194],"dose":[195],"retained":[196],"after":[197],"6h)":[198],"intratracheal":[200],"administration":[201],"long-acting":[206],"sheep":[210],"model":[211],"mucociliary":[213],"clearance":[214],"inhalation":[216],"(ED":[217],"100":[218],"(4\u20136h)":[219],"=":[220],"9":[221],"\u03bcg/kg).":[222],"entered":[224],"phase":[226],"II":[227],"study":[228],"CF":[230],"patients":[231],"July":[233],"2024.":[234]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2024-11-09T00:00:00"}